Results For "Dr.-Ashkan-Shoamanesh"

1 News Found

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

Diagnostic Center | September 01, 2022

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke

Latest Stories

Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution

Mankind Pharma launches 'Limit White India' campaign to raise hypertension awareness

Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Dr. R. Ananthanarayanan CEO, Sajjan India

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region

We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region

Vinod Paremal President & MD, Evonik, India Region

Packaging